Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239192 | 0.91 | CHEK2 (0.57) | CHEK2DHODHKDRLMNAMAPT | |
| SCHEMBL4246152 | 0.87 | DHODH (0.52) | CHEK2DHODHPLAUSIRT2SIRT1 | |
| SCHEMBL4240843 | 0.85 | TDP1 (0.53) | CHEK2DHODHLMNAMAPTRAB9A | |
| SCHEMBL4244333 | 0.80 | PARP1 (0.48) | DHODHKDRLMNAMAPTHPGD | |
| SCHEMBL4248322 | 0.79 | CSNK2A1 (0.53) | DHODHBRAFKDRLMNAPIM1 | |
| SCHEMBL4246328 | 0.79 | KDR (0.55) | KDRMAPTHPGDRAB9AMAPK1 | |
| SCHEMBL4247671 | 0.78 | CHEK2 (0.53) | CHEK2DHODHGSK3BPOLB | |
| SCHEMBL4235724 | 0.78 | IMPDH2 (0.47) | CHEK2PRKD3PIM1PRKACAGSK3A | |
| SCHEMBL4246266 | 0.78 | PKN1 (0.53) | DHODHKDRLMNAHPGDRAB9A | |
| SCHEMBL4239198 | 0.78 | PNLIP (0.54) | CHEK2DHODHKDRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CHEK2 3480/4885DHODH 907/4885PLAU 2055/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CHEK2 3480/4885DHODH 907/4885PLAU 2055/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CHEK2 3480/4885DHODH 907/4885PLAU 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.